Maven Semantic updates Urinary Incontinence research database

Maven Semantic ( announces updates to their Urinary Incontinence research database.

“, based on where they work, their job title, how many times they have published, where they have published, etc. The relevance can be fine tuned by the user”

The new database is now available to marketing, business development, competitor intelligence, KOL, medical affairs and related departments in the life sciences sector.

The database currently tags 14,000 individuals working in Urinary Incontinence.

Top 10 Countries for Urinary Incontinence Research (ranked by number of senior Urinary Incontinence researchers)

  • United States Of America (4,276)
  • United Kingdom (1,161)
  • Japan (605)
  • France (590)
  • Germany (472)
  • Italy (444)
  • Canada (353)
  • The Netherlands (342)
  • Sweden (299)
  • Turkey (292)

Leading organisations in Urinary Incontinence research include:

  • University of California
  • University of Toronto
  • Harvard Medical School
  • Mayo Clinic
  • Duke University Medical Center
  • University of Michigan
  • Cleveland Clinic Foundation
  • University of Copenhagen
  • University of Pittsburgh School of Medicine
  • Baylor College of Medicine
  • Southmead Hospital
  • University College London
  • University of Texas Southwestern Medical Center
  • King's College Hospital
  • Bristol Urological Institute
  • Washington University School of Medicine
  • University of Bergen
  • Chang Gung Memorial Hospital
  • All India Institute of Medical Sciences
  • New York University School of Medicine
  • William Beaumont Hospital
  • University of Iowa
  • University of Leicester
  • James Buchanan Brady Urological Institute

The database also includes pharmaceutical companies, biotech companies, CROs, hospitals, government labs and other organisations active in the Urinary Incontinence research field.

Sample companies in database include:

  • Nippon Shinyaku Co., Ltd
  • Eli Lilly and Company
  • Pfizer Inc
  • Lilly Research Laboratories, Eli Lilly and Company
  • Nova Pharmaceutical Corporation
  • United BioSource Corporation
  • Astellas Pharma Inc
  • KabiVitrum AB
  • Kyorin Pharmaceutical Co., Ltd
  • MEDTAP International, Inc
  • NOVA Pharmaceutical Corporation
  • Nippon Shinyaku Co. Ltd
  • Novartis Pharmaceuticals Corporation
  • Taiho Pharmaceutical Co., Ltd
  • Urology Associates
  • ALZA Corporation
  • APOGEPHA Arzneimittel GmbH
  • Advanced Bionics Corporation
  • Allergan (UK) Ltd
  • Bioelastic Research, Ltd
  • Boehringer Ingelheim GmbH

What is Maven:

- Largest database of international medical professionals, with over 6,000,000 people and over 500,000 medical organisations;

- All records are downloadable to excel or in-house database, with email, postal address and phone contacts;

- Profile and segment the entire database using over 47,000 diseases and therapeutic areas

What is Maven used for:

- Building prospect lists for postal, telesales and email campaigns

- Locating key decision makers in companies, hospitals, government labs, university labs, and other healthcare facilities

- Identifying candidates for recruitment to very specific life science positions

About the Maven Semantic Medical Database: The current database holds over 6 million medical professionals, and 500,000 medical organisations.

The Maven Semantic medical database covers pharmaceutical, biotech and medical device companies, clinical research labs, hospitals, medical universities and government research organisations.

Maven is a SaaS subscription-based service. Clients can choose from quarterly or yearly subscriptions, or as pay-as-you-go option to retrieve specific large datasets for in-house use.

Results can be viewed online, or exported to Excel or a CRM system.

The data is now available to international healthcare marketing teams.


Maven Semantic


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
You might also like... ×
Experts say cancer research is making more progress that people think